The company
enGene Therapeutics Inc.
ENGN · Nasdaq
ENGN stood above a rising 150-day average in 20 of the last 52 weekly readings, and has been out of that trend for the last 32 weeks. It is 47.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 32
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $20K
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 0
- Institutions holding
- 57 (-2)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 20 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| William GrossmanInterim Chief Medical Officer | bought | 5,102at $1.97 | 22 Sep 2026filed 24 Sep 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FCPM III SERVICES B.V.unchanged · filed 14 Aug 2026 | 9,632,561$16.7M | 00.0% |
| BML Capital Management, LLCnew · filed 7 Aug 2026 | 6,669,908$11.5M | +6,669,908 |
| Siren, L.L.C.added · filed 13 Aug 2026 | 6,256,662$10.8M | +1,003,503+19.1% |
| PERCEPTIVE ADVISORS LLCreduced · filed 14 Aug 2026 | 4,822,169$8.3M | -1,005,337−17.3% |
| AMERIPRISE FINANCIAL INCnew · filed 14 Aug 2026 | 2,675,876$4.6M | +2,675,876 |
| Nextech Invest Ltd.unchanged · filed 14 Aug 2026 | 2,324,943$4.0M | 00.0% |
| ADAR1 Capital Management, LLCadded · filed 14 Aug 2026 | 2,104,986$3.6M | +1,971,300+1474.6% |
| Vestal Point Capital, LPreduced · filed 14 Aug 2026 | 1,667,430$2.9M | -497,570−23.0% |
| ACORN CAPITAL ADVISORS, LLCnew · filed 14 Aug 2026 | 1,271,257$2.2M | +1,271,257 |
| Peapod Lane Capital LLCnew · filed 27 Jul 2026 | 1,102,149$1.9M | +1,102,149 |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.